Treatments Expanding for Metastatic Prostate Cancer

<!DOCTYPE html> <html lang="en" dir="ltr" prefix="og: https://ogp.me/ns#"> <head> <meta http-equiv="X-UA-Compatible" content="IE=edge"> <meta charset="utf-8" /> <script>window.CDEConfig = { "exitDisclaimerHref":{ "en":"\/policies\/linking", "es":"\/espanol\/politicas\/enlaces" }, "showFloatingDelighters":true, "environmentConfig":{ }, "glossaryConfig":{ "apiServer":"https:\/\/webapis.cancer.gov\/glossary\/v1\/" }, "drugDictionaryConfig":{ "apiServer":"https:\/\/webapis.cancer.gov\/drugdictionary\/v1\/" }, "ctsConfig":{ "apiServer":"https:\/\/clinicaltrialsapi.cancer.gov\/api\/v2", "printApiBase":"https:\/\/www.cancer.gov\/CTS.Print", "zipConversionEndpoint":"\/cts_api\/zip_code_lookup" }, "r4rConfig":{ "apiServer":"https:\/\/webapis.cancer.gov\/r4r\/v1" }, "general":{ "apiServer":"https:\/\/webapis.cancer.gov", "mediaServer":"https:\/\/nci-media.cancer.gov" }, "sitewideSearchConfig":{ "bestBetsApiServer":"https:\/\/webapis.cancer.gov\/bestbets\/v1\/", "searchApiServer":"https:\/\/webapis.cancer.gov\/sitewidesearch\/v1\/" }, "chartData": { "factBook": { "baseUrl": "\/about-nci\/budget\/fact-book", "dataType": "json" } } };</script> <script id="ncids-nav-info">window.ncidsNavInfo = { nav: { id: "860258", menu_type: "section-nav"}, item_id: 860258};</script> <meta name="description" content="Enzalutamide (Xtandi) and apalutamide (Erleada), respectively, improved the survival of men with hormone-sensitive metastatic prostate cancer, in two large trials." /> <link rel="canonical" href="https://www.cancer.gov/news-events/cancer-currents-blog/2019/enzalutamide-apalutamide-metastatic-prostate-cancer" /> <meta http-equiv="content-language" content="en" /> <meta name="robots" content="index" /> <meta property="og:type" content="Website" /> <meta property="og:url" content="https://www.cancer.gov/news-events/cancer-currents-blog/2019/enzalutamide-apalutamide-metastatic-prostate-cancer" /> <meta property="og:title" content="Treatments Expanding for Metastatic Prostate Cancer" /> <meta property="og:description" content="Enzalutamide (Xtandi) and apalutamide (Erleada), respectively, improved the survival of men with hormone-sensitive metastatic prostate cancer, in two large trials." /> <meta property="og:image" content="https://www.cancer.gov/sites/g/files/xnrzdm211/files/styles/cgov_social_media/public/cgov_image/media_image/100/800/3/files/androgen-receptor-enlarge.jpg" /> <meta name="cgdp.domain" content="cgov" /> <meta name="cgdp.template" content="default" /> <meta name="dcterms.subject" content="News and Events" /> <meta name="dcterms.type" content="cgvBlogPost" /> <meta name="dcterms.coverage" content="nciglobal,ncienterprise" /> <meta name="dcterms.isPartOf" content="CancerCurrents" /> <meta name="dcterms.isReferencedBy" content="event1,event53" /> <meta name="dcterms.issued" content="06/19/2019 - 08:00" /> <meta name="twitter:card" content="summary" /> <link rel="icon" href="https://www.cancer.gov/profiles/custom/cgov_site/themes/custom/cgov/static/images/design-elements/icons/favicons/favicon.ico" sizes="32x32"/> <link rel="icon" href="https://www.cancer.gov/profiles/custom/cgov_site/themes/custom/cgov/static/images/design-elements/icons/favicons/favicon.svg" type="image/svg+xml"/> <link rel="apple-touch-icon" href="https://www.cancer.gov/profiles/custom/cgov_site/themes/custom/cgov/static/images/design-elements/icons/favicons/apple-touch-icon.png"/> <link rel="manifest" href="https://www.cancer.gov/profiles/custom/cgov_site/themes/custom/cgov/static/images/design-elements/icons/favicons/site.webmanifest"/> <meta name="x-no-op" content="none" /> <meta name="Generator" content="Drupal 10 (https://www.drupal.org)" /> <meta name="MobileOptimized" content="width" /> <meta name="HandheldFriendly" content="true" /> <meta name="viewport" content="width=device-width, user-scalable=yes, initial-scale=1, minimum-scale=1" /> <script id="cgov-adobe-url" type="text/javascript" src="//assets.adobedtm.com/6a4249cd0a2c/949e98979342/launch-5f2a5357bf66.min.js" async="async"></script> <script type="application/ld+json">{ "@context": "https://schema.org", "@graph": [ { "@type": "WebSite", "name": "National Cancer Institute (.gov)", "url": "https://www.cancer.gov" } ] }</script> <link rel="alternate" hreflang="en" href="https://www.cancer.gov/news-events/cancer-currents-blog/2019/enzalutamide-apalutamide-metastatic-prostate-cancer" /> <link rel="alternate" hreflang="es" href="https://www.cancer.gov/espanol/noticias/temas-y-relatos-blog/2019/enzalutamide-apalutamide-cancer-prostata-metastatico" /> <title>Treatments Expanding for Metastatic Prostate Cancer - NCI</title> <link rel="preconnect" href="https://static.cancer.gov" /> <link rel="preconnect" href="https://fonts.googleapis.com"> <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin> <link href="https://fonts.googleapis.com/css2?family=Open+Sans:ital,wght@0,300;0,400;0,600;0,700;1,300;1,400;1,600;1,700&family=Poppins:ital,wght@0,300;0,400;0,500;0,600;1,300;1,400;1,500;1,600&family=Roboto+Mono:ital,wght@0,300;0,400;0,700;1,300;1,400;1,700&display=swap" rel="stylesheet"> <meta name="apple-mobile-web-app-title" content="Cancer.gov" /> <meta name="application-name" content="Cancer.gov" /> <link rel="stylesheet" media="all" href="/sites/g/files/xnrzdm211/files/css/css_2MGzP4wXbQkUEoIIdFZZMVDesqPLoVgfQ4Jd23xDS6k.css?delta=0&language=en&theme=ncids_trans&include=eJxFyEEOwCAIBMAPGX1SA4WoCVXCyqG_77FzHLw4-jQmaHEK6kE-0CTSyeo_NZcn28RQKeuegusELTS23fEB1Owbrg" /> <link rel="stylesheet" media="all" href="/profiles/custom/cgov_site/themes/custom/ncids_trans/dist/css/ncids-common.css?smm34w" /> <link rel="stylesheet" media="all" href="/profiles/custom/cgov_site/themes/custom/ncids_trans/dist/css/blogs.css?smm34w" /> </head> <body class="has-translated-content"> <a href="#main-content" class="usa-skipnav"> Skip to main content </a> <div class="dialog-off-canvas-main-canvas" data-off-canvas-main-canvas> <section id="usa-banner" class="usa-banner" aria-label="Official government website"> <header class="usa-banner__header"> <div class="usa-banner__inner"> <div class="usa-banner__header-text"> An official website of the United States government </div> <a href="/espanol/noticias/temas-y-relatos-blog/2019/enzalutamide-apalutamide-cancer-prostata-metastatico" id="lang-toggle" class="usa-button usa-button--nci-small" hreflang="es">Español</a> </div> </header> </section> <header id="nci-header" class="nci-header nci-header--megamenu" data-base-path="/"> <div class="nci-header__navbar"> <div class="nci-logo" id="extended-mega-logo"> <a href="/" aria-label="National Cancer Institute Home Page"> <picture><source media="(min-width: 1024px)" srcset="/sites/g/files/xnrzdm211/files/ncids_header/logos/Logo_NCI.svg" /> <img src="/sites/g/files/xnrzdm211/files/ncids_header/logos/Logo_NCI_Mobile.svg" alt="" /> </picture> </a> </div> <div class="nci-header-nav__secondary"> <button class="usa-button nci-header-mobilenav__open-btn">Menu</button> <form class="nci-header-search" method="get" action="/search/results" role="search"> <label class="usa-sr-only" for="nci-header-search__field"> Search </label> <input class="usa-input" id="nci-header-search__field" type="search" name="swKeyword" data-autosuggest-collection="cgov"/> <button class="usa-button nci-header-search__search-button" type="submit" aria-label="Search"> <span class="nci-header-search__label" aria-hidden="true">Search</span> <svg class="usa-icon" xmlns="http://www.w3.org/2000/svg" role="img" viewbox="0 0 24 24" aria-hidden="true"> <path d="M0 0h24v24H0z" fill="none"/> <path d="M15.5 14h-.79l-.28-.27C15.41 12.59 16 11.11 16 9.5 16 5.91 13.09 3 9.5 3S3 5.91 3 9.5 5.91 16 9.5 16c1.61 0 3.09-.59 4.23-1.57l.27.28v.79l5 4.99L20.49 19l-4.99-5zm-6 0C7.01 14 5 11.99 5 9.5S7.01 5 9.5 5 14 7.01 14 9.5 11.99 14 9.5 14z"/> </svg> </button> </form> </div> </div> <nav aria-label="Primary navigation" class="nci-header-nav"> <div class="nci-header-nav__inner"> <ul class="nci-header-nav__primary"> <li class="nci-header-nav__primary-item"> <a href="/about-cancer" class="nci-header-nav__primary-link" data-menu-id="829"> <span>About Cancer</span> </a> </li> <li class="nci-header-nav__primary-item"> <a href="/types" class="nci-header-nav__primary-link" data-menu-id="11868"> <span>Cancer Types</span> </a> </li> <li class="nci-header-nav__primary-item"> <a href="/research" class="nci-header-nav__primary-link" data-menu-id="12732"> <span>Research</span> </a> </li> <li class="nci-header-nav__primary-item"> <a href="/grants-training" class="nci-header-nav__primary-link" data-menu-id="914792"> <span>Grants & Training</span> </a> </li> <li class="nci-header-nav__primary-item"> <a href="/news-events" class="nci-header-nav__primary-link usa-current" data-menu-id="12664"> <span>News & Events</span> </a> </li> <li class="nci-header-nav__primary-item"> <a href="/about-nci" class="nci-header-nav__primary-link" data-menu-id="10952"> <span>About NCI</span> </a> </li> </ul> </div> </nav> </header> <div class="grid-container"> <div class="grid-row flex-no-wrap"> <div class="grid-col-10"> <nav class="usa-breadcrumb usa-breadcrumb--wrap" aria-label="Breadcrumbs"> <ol class="usa-breadcrumb__list"> <li class="usa-breadcrumb__list-item"> <a href="/" class="usa-breadcrumb__link"> <span>Home</span> </a> </li> <li class="usa-breadcrumb__list-item"> <a href="/news-events" class="usa-breadcrumb__link"> <span>News & Events</span> </a> </li> <li class="usa-breadcrumb__list-item"> <a href="/news-events/cancer-currents-blog" class="usa-breadcrumb__link"> <span>Cancer Currents Blog</span> </a> </li> <li class="usa-breadcrumb__list-item usa-current" aria-current="page"> <span>More Treatment Options Emerging for Some Men with Metastatic Prostate Cancer</span> </li> </ol> </nav> </div> <section class="cgdp-page-options cgdp-page-options--top" aria-label="Page options top"> <button class="usa-button usa-button--unstyled" onclick="window.print()"> <svg xmlns="http://www.w3.org/2000/svg" height="24" viewBox="0 0 24 24" width="24" class="usa-icon" role="img" aria-hidden="true" focusable="false"> <path d="M0 0h24v24H0z" fill="none"/> <path d="M19 8H5c-1.66 0-3 1.34-3 3v6h4v4h12v-4h4v-6c0-1.66-1.34-3-3-3zm-3 11H8v-5h8v5zm3-7c-.55 0-1-.45-1-1s.45-1 1-1 1 .45 1 1-.45 1-1 1zm-1-9H6v4h12V3z"/> </svg> <span class="usa-sr-only"> Print </span> </button> <a class="usa-button usa-button--unstyled" href="mailto:?subject=Information from the National Cancer Institute Web Site &body=I found this information on www.cancer.gov and I'd like to share it with you: https://www.cancer.gov/news-events/cancer-currents-blog/2019/enzalutamide-apalutamide-metastatic-prostate-cancer %0D%0A%0D%0A NCI's Web site, www.cancer.gov, provides accurate, up-to-date, comprehensive cancer information from the U.S. government's principal agency for cancer research. If you have questions or need additional information, we invite you to contact NCI's LiveHelp instant messaging service at https://livehelp.cancer.gov, or call the NCI's Contact Center 1-800-4-CANCER (1-800-422-6237) (toll-free from the United States)."> <svg xmlns="http://www.w3.org/2000/svg" height="24" viewBox="0 0 24 24" width="24" class="usa-icon" role="img" aria-hidden="true" focusable="false"> <path d="M0 0h24v24H0z" fill="none"/> <path d="M20 4H4c-1.1 0-1.99.9-1.99 2L2 18c0 1.1.9 2 2 2h16c1.1 0 2-.9 2-2V6c0-1.1-.9-2-2-2zm0 14H4V8l8 5 8-5v10zm-8-7L4 6h16l-8 5z"/> </svg> <span class="usa-sr-only"> Email </span> </a> </section> </div> </div> <div id="page" class="grid-container"> <div class="grid-row grid-gap"> <div data-drupal-messages-fallback class="hidden"></div> <div class="cgdpl desktop:grid-col-9"> <main id="main-content" class="contentzone"> <div>  <article> <div class="resize-content"> <h1> More Treatment Options Emerging for Some Men with Metastatic Prostate Cancer </h1> <div id="nvcgSubTitle"> <div class="subscribeRSS"> <a class="blogRSS" href="https://public.govdelivery.com/accounts/USNIHNCI/subscriber/new?topic_id=USNIHNCI_38"><span>Subscribe</span></a> </div> </div> <div id="cgvBody" class="cgvblogpost"> <p class="blog-post-publishing-info"> <time datetime="2019-06-19T12:00:00Z">June 19, 2019</time>, by NCI Staff </p> <div data-entity-embed-display="view_mode:media.image_display_article_medium" class="embedded-entity align-right"> <figure class="image-medium centered-set"> <div class="centered-element"> <img loading="lazy" longdesc="/media/1148733/long-description" src="/sites/g/files/xnrzdm211/files/styles/cgov_article/public/cgov_image/media_image/100/800/3/files/androgen-receptor-enlarge.jpg?h=04921507&itok=XOLdtSM9" width="717" height="588" alt="" /> <a href="/sites/g/files/xnrzdm211/files/styles/cgov_enlarged/public/cgov_image/media_image/100/800/3/files/androgen-receptor-enlarge.jpg?h=04921507&itok=tNXIH7tg" target="_blank" class="article-image-enlarge no-resize" >Enlarge</a> </div> <figcaption> <div class="caption-container no-resize"> <p>Enzalutamide and apalutamide block the androgen receptor (AR) on cancer cells, blunting androgen's (A) ability to fuel prostate cancer growth.</p> <div class="image-photo-credit">Credit: Cancers 2017. doi:10.3390/cancers9020020. CC BY 4.0.</div> </div> </figcaption> </figure> </div> <div class="blog-intro-text"> <p>On September 17, 2019, the Food and Drug Administration approved apalutamide (Erleada) for men with metastatic, castration-sensitive prostate cancer. The approval was based on the results from the TITAN trial, which showed that apalutamide combined with androgen deprivation therapy (ADT) improved overall survival and radiographic progression-free survival compared with ADT alone. Further details on the trial results are discussed in the article below.</p></div> <p>The treatment landscape for metastatic prostate cancer is shifting and expanding yet again, according to new findings from two large clinical trials presented at the 2019 annual meeting of the American Society of Clinical Oncology (ASCO).</p> <p>The ENZAMET trial tested the drug <span><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="d1b35b82-7a0f-4a3e-ade0-b3817c2cc54a" href="/about-cancer/treatment/drugs/enzalutamide">enzalutamide (Xtandi)</a></span> and the TITAN trial tested <span><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="13c33a5b-3a6a-4456-857b-4536607787b5" href="/about-cancer/treatment/drugs/apalutamide">apalutamide (Erleada)</a></span> in men whose cancer is still responsive to hormone-suppressing therapies—also called <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000045636&version=Patient&language=English" onclick="javascript:popWindow('defbyid','CDR0000045636&version=Patient&language=English'); return false;">castration</a>-sensitive prostate cancer. In both trials, combining the respective drugs with the <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000559086&version=Patient&language=English" onclick="javascript:popWindow('defbyid','CDR0000559086&version=Patient&language=English'); return false;">androgen deprivation therapy</a> (ADT) substantially improved how long men lived overall and how long they lived without their cancer getting worse.</p> <p>Results from both trials were also simultaneously published in the <em>New England Journal of Medicine</em>.</p> <p>Enzalutamide and apalutamide are already approved by the Food and Drug Administration to treat prostate cancer that no longer responds to therapies that reduce levels of the hormone <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000045592&version=Patient&language=English" onclick="javascript:popWindow('defbyid','CDR0000045592&version=Patient&language=English'); return false;">androgen</a>, known as <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000686083&version=Patient&language=English" onclick="javascript:popWindow('defbyid','CDR0000686083&version=Patient&language=English'); return false;">hormone-resistant</a> (or castration-resistant) disease. Those approvals are expected to expand based on these new data.</p> <p>From a treatment perspective, the trials’ findings now mean that “there are more treatment options for patients,” said William Dahut, M.D., the clinical director in NCI’s <span><a href="https://ccr.cancer.gov/">Center for Cancer Research</a>,</span> who specializes in treating prostate cancer but was not involved in either study.</p> <p>Speaking at the ASCO meeting, Tanya Dorff, M.D., head of the genitourinary cancers program at the City of Hope Comprehensive Cancer Center in California, agreed. The trials also confirm the value of intensifying treatment in men with hormone-sensitive metastatic prostate cancer, Dr. Dorff said, “rather than being reserved for castration-resistant patients.”</p> <h2>In Five Years, a Major Treatment Shift</h2> <p>In men diagnosed with metastatic hormone-sensitive prostate cancer, the cancer is typically driven to grow and spread by androgens that are produced largely in the testes. For many years, treatments that block androgen production have been a mainstay for men initially diagnosed with metastatic prostate cancer.</p> <p>Starting in 2014, that began to change after a large clinical trial showed that adding the chemotherapy drug <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000045382&version=Patient&language=English" onclick="javascript:popWindow('defbyid','CDR0000045382&version=Patient&language=English'); return false;">docetaxel</a> to ADT <a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="c8c5e040-ffdc-498b-a9dd-b98c248871aa" href="/types/prostate/research/chemohormonal-treatment-extends-survival">improved how long men with hormone-responsive disease lived</a>. Shortly after, another clinical trial showed that adding <a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="a0a27515-a81a-45b0-b48f-851f3a7b7347" href="/about-cancer/treatment/drugs/abirateroneacetate">abiraterone (Zytiga)</a> to ADT also improved survival in these men, although <a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="335ea9c1-9016-4f95-953f-c9858254f8f5" href="/news-events/cancer-currents-blog/2017/abiraterone-hormone-sensitive-prostate">primarily in men with many metastatic tumors</a>, known as high-volume disease.</p> <p>However, docetaxel, which works by directly killing cancer cells, can have substantial side effects, and some patients aren’t healthy enough to tolerate it. And abiraterone—which blocks androgen production throughout the body—can also cause side effects, including those that affect the liver. It also has to be given in combination with the steroid prednisone, which carries its own toxicity.</p> <p>Enzalutamide and apalutamide block the androgen receptor on cancer cells, blunting androgens’ ability to fuel prostate cancer growth. The drugs’ efficacy in hormone-resistant metastatic prostate cancer led researchers to test them in men with less advanced disease. The goal was to see if they could “provide more complete reduction of androgen signaling” in hormone-responsive prostate cancer cells, explained Kim Chi, M.D., of the BC Cancer Agency in Vancouver, a lead investigator on the TITAN trial.</p> <p>Doing so, Dr. Chi said during a presentation of the TITAN data at the ASCO meeting, might help stave off the typically inevitable development of hormone-resistant cancer, which is more difficult to treat and a key driver of prostate cancer deaths.</p> <h2>Improving How Long Patients Live</h2> <p>The ENZAMET trial—funded in part by the drug’s manufacturer, Astellas Pharma, as well as government health agencies in Canada and Australia—enrolled more than 1,100 men (largely outside of the United States) with hormone-sensitive metastatic prostate cancer. The men were randomly assigned to ADT combined with enzalutamide or with any of three other androgen-blocking drugs.</p> <p>At a median follow-up of nearly 3 years, <a href="https://www.ncbi.nlm.nih.gov/pubmed/31157964">men who received ADT plus enzalutamide had a 33% reduced risk of death</a>, with 80% still alive compared with 72% of men treated with ADT plus another antiandrogen drug, reported the trial’s lead investigator, Christopher Sweeney, M.B.B.S., of the Dana-Farber Cancer Institute.</p> <p>Men in the enzalutamide group also had better clinical <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000044782&version=Patient&language=English" onclick="javascript:popWindow('defbyid','CDR0000044782&version=Patient&language=English'); return false;">progression-free survival</a> (PFS), which the research team defined as the time until the return of disease-related symptoms, the detection of new metastases on <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000045720&version=Patient&language=English" onclick="javascript:popWindow('defbyid','CDR0000045720&version=Patient&language=English'); return false;">imaging scans</a>, or the initiation of another cancer treatment for prostate cancer, whichever came first. At 3 years, 63% of men in the enzalutamide group were alive without clinical progression of their disease, compared with 33% in the <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000044930&version=Patient&language=English" onclick="javascript:popWindow('defbyid','CDR0000044930&version=Patient&language=English'); return false;">standard treatment</a> group.</p> <p>Although enzalutamide appeared to be effective regardless of whether men had high- or low-volume disease, one apparent differentiating factor was planned early treatment with docetaxel. Nearly half of the men in both treatment groups received early treatment with docetaxel and, for those men, enzalutamide was not associated with longer <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000655245&version=Patient&language=English" onclick="javascript:popWindow('defbyid','CDR0000655245&version=Patient&language=English'); return false;">overall survival</a>.</p> <p>Side effects and serious side effects were more common in men treated with enzalutamide, including increased blood pressure and fatigue. In men who also received docetaxel, the rate of <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000044705&version=Patient&language=English" onclick="javascript:popWindow('defbyid','CDR0000044705&version=Patient&language=English'); return false;">peripheral neuropathy</a> was more than tripled in the enzalutamide group. Seven men treated with enzalutamide experienced seizures, compared with no men in the standard treatment group, and overall more than twice as many men receiving enzalutamide stopped treatment (33 versus 14).</p> <p>From the standpoint of efficacy, similar results were seen in the TITAN trial with apalutamide. Funded by the drug’s manufacturer, Janssen Pharmaceuticals, the trial enrolled more than 1,000 men with hormone-sensitive metastatic prostate cancer, with participants randomly assigned to receive ADT along with a placebo or ADT plus apalutamide.</p> <p>At 2 years of follow-up, <a href="https://www.ncbi.nlm.nih.gov/pubmed/31150574">approximately 82% of men who received ADT plus apalutamide were still alive</a>, compared with 74% in men treated with ADT plus placebo, for a 33% reduction in the risk of death. The trial’s other primary measure was the amount time men lived without evidence on imaging scans that their disease had progressed, known as radiographic PFS. At a median follow-up of nearly 2 years, men treated with ADT plus apalutamide had a 50% improvement in radiographic PFS than men treated with ADT alone.</p> <p>Rash was one of the most common side effects among men treated with apalutamide, with more than a quarter experiencing this problem. For most men, the rash did not cause symptoms, but it was still the primary reason for men stopping apalutamide treatment, Dr. Chi said.</p> <p>The drug also appeared to be effective across different subgroups of patients, including men with low-volume and high-volume cancer. At the time of the last analysis of the data, Dr. Chi noted, approximately two-thirds of men in the apalutamide arm were still taking the drug.</p> <h2>How to Choose?</h2> <p>More treatment options also require clinicians and patients to make more decisions. In the case of enzalutamide and apalutamide, Dr. Dahut said, both drugs “may be particularly good choices for men with low-volume disease, who might shy away from docetaxel” due to concerns about side effects.</p> <p>Unlike docetaxel, which must be administered intravenously in the hospital, enzalutamide, apalutamide, and abiraterone are oral drugs that can be taken at home, so they also offer greater convenience for patients. On the other hand, many patients tolerate docetaxel quite well, Dr. Dahut noted, and it’s given for a fixed duration, not continuously like the other drugs.</p> <p>Cost might also be a consideration when it comes to the three hormone therapy drugs, explained Michael Carducci, M.D., who specializes in treating prostate cancer at Johns Hopkins University Sidney Kimmel Cancer Center.</p> <p>“Our underinsured patients have struggled to cover the cost of these medications,” he said.</p> <p>Speaking during an ASCO session on the TITAN findings, Dr. Carducci added that other factors, such as age, can influence treatment decisions. When older patients “hear about some of the side effects [of these drugs], they don’t want to feel old or frail,” he said. So while they are willing to undergo ADT, “the idea of adding more therapy … remains a problem.”</p> <p>Researchers are continuing to identify potential <a class="definition" href="/Common/PopUps/popDefinition.aspx?id=CDR0000045618&version=Patient&language=English" onclick="javascript:popWindow('defbyid','CDR0000045618&version=Patient&language=English'); return false;">biomarkers</a> or specific clinical factors that can identify which patients might be the best candidates for a given treatment, Dr. Dorff noted. In the meantime, she said, clinicians “will need shared, informed decision making with our patients.”</p> <p>And although there is the possibility of combining these different treatments, she stressed, “combinations have not yet proven to be beneficial and should not be offered outside of a clinical trial.”</p> </div> </div> <footer class="article-footer"> <div id='cgov-blog-post-pagination' class='clearfix'> <div class='blog-post-older'> <a href="/news-events/cancer-currents-blog/2019/venetoclax-obinutuzumab-fda-approval-cll-sll">< Older Post</a> <p><i>Combination Therapy with Venetoclax Approved for Chronic Lymphocytic Leukemia </i></p> </div> <div class='blog-post-newer'> <a href="/news-events/cancer-currents-blog/2019/pancreatic-cancer-olaparib-brca-mutations">Newer Post ></a> <p><i>Trial Highlights Complexities of Targeted Therapy for Pancreatic Cancer</i></p> </div> </div> <div id="blog-cards"> <h2 class="recommended-content__header">Recommended From NCI</h2> <div id="nvcgSlLayoutFeatureA" class="row flex-columns"> <div class="slot-item equalheight large-4 columns card gutter blog-feature"> <div class="feature-card cgvBlogPost"> <a href="/news-events/cancer-currents-blog/2018/apalutamide-fda-nonmetastatic-prostate"> <div class="image-hover"> <img loading="lazy" src="/sites/g/files/xnrzdm211/files/styles/cgov_featured/public/cgov_image/media_image/100/900/0/files/cancer-spreading-to-the-bone-article.jpg?h=90fd3a82&itok=e7GfKRFP" width="425" height="319" alt="" /> </div> <h3>FDA Approves Apalutamide for Prostate Cancer</h3> </a> </div> </div> <div class="slot-item equalheight large-4 columns card gutter blog-feature"> <div class="feature-card cgvBlogPost"> <a href="/news-events/cancer-currents-blog/2017/prostate-cancer-resistant-new-subtype"> <div class="image-hover"> <img loading="lazy" src="/sites/g/files/xnrzdm211/files/styles/cgov_featured/public/cgov_image/media_image/100/000/8/files/prostate-cancer-stage-iv-article.jpg?h=062db150&itok=8nuqDNHR" width="425" height="319" alt="" /> </div> <h3>New Subtype of Treatment-Resistant Prostate Cancer</h3> </a> </div> </div> <div class="slot-item equalheight large-4 columns card gutter blog-feature"> <div class="feature-card cgvBlogPost"> <a href="/news-events/cancer-currents-blog/2018/high-fat-diet-prostate-metastasis"> <div class="image-hover"> <img loading="lazy" src="/sites/g/files/xnrzdm211/files/styles/cgov_featured/public/cgov_image/media_image/100/700/5/files/high-fat-meal-article.jpg?h=fd38ee9e&itok=8yYp31F0" width="425" height="319" alt="" /> </div> <h3>High-Fat Diet Linked to Prostate Cancer Metastasis</h3> </a> </div> </div> </div> <div> <div id="nvcgSlPublicUse"> <div class="slot-item only-SI"> <div class="public-use"> <div id="block-ncids-trans-public-use"> <p><em>If you would like to reproduce some or all of this content, see <a href="/policies/copyright-reuse">Reuse of NCI Information</a> for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “More Treatment Options Emerging for Some Men with Metastatic Prostate Cancer was originally published by the National Cancer Institute.”</em></p> </div> </div> </div> </div> </footer> </article>  </div> </main> </div>   <div class="cgdpl desktop:grid-col-3"> <div id="nvcgSlListBlogRTRail" class="right-rail"> <div class="slot-item"> <div class="managed list with-date"> <h2 id="Featured+Posts">Featured Posts</h2> <ul> <li class="general-list-item general list-item"> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog/2024/medical-cannabis-oncologists-patients-communication">Oncologists Struggle to Answer Questions About Medical Cannabis</a> <div class="byline"> <p> October 16, 2024, by Carmen Phillips </p> </div> </div> </li> <li class="general-list-item general list-item"> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog/2024/mammogram-false-positives-affect-future-screening">Mammogram False Positives Can Affect Future Screening Behavior</a> <div class="byline"> <p> October 4, 2024, by Edward Winstead </p> </div> </div> </li> <li class="general-list-item general list-item"> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog/2024/ancient-retrovirus-dna-ltr10-cancer">DNA From an Ancient Virus Helps Many Cancers Grow</a> <div class="byline"> <p> September 6, 2024, by Nadia Jaber </p> </div> </div> </li> </ul> </div> </div> <div class="slot-item"> <div class="managed list without-date"> <h2 id="Categories">Categories</h2> <ul> <li class="general-list-item general list-item"> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog?topic=biology">Biology of Cancer</a> </div> </li> <li class="general-list-item general list-item"> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog?topic=cancer-risk">Cancer Risk</a> </div> </li> <li class="general-list-item general list-item"> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog?topic=childhood-cancer">Childhood Cancer</a> </div> </li> <li class="general-list-item general list-item"> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog?topic=clinical-trial-results">Clinical Trial Results</a> </div> </li> <li class="general-list-item general list-item"> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog?topic=disparities">Disparities</a> </div> </li> <li class="general-list-item general list-item"> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog?topic=fda-approvals">FDA Approvals</a> </div> </li> <li class="general-list-item general list-item"> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog?topic=global-health">Global Health</a> </div> </li> <li class="general-list-item general list-item"> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog?topic=leadership-expert-views">Leadership & Expert Views</a> </div> </li> <li class="general-list-item general list-item"> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog?topic=prevention">Prevention</a> </div> </li> <li class="general-list-item general list-item"> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog?topic=prognosis">Prognosis</a> </div> </li> <li class="general-list-item general list-item"> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog?topic=screening-early-detection">Screening & Early Detection</a> </div> </li> <li class="general-list-item general list-item"> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog?topic=survivorship-supportive-care">Survivorship & Supportive Care</a> </div> </li> <li class="general-list-item general list-item"> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog?topic=technology">Technology</a> </div> </li> <li class="general-list-item general list-item"> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog?topic=treatment">Treatment</a> </div> </li> </ul> </div> </div> <div class="slot-item"> <div class="desktop"> <div id="blog-archive-accordion"> <h2 id="archive" class="blog-archive-header"> Archive </h2> <div id="blog-archive-accordion-year"> <h3> 2024 </h3> <ul class="ui-helper-reset"> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2024&month=11"> November </a> (5) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2024&month=10"> October </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2024&month=09"> September </a> (5) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2024&month=08"> August </a> (9) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2024&month=07"> July </a> (6) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2024&month=06"> June </a> (5) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2024&month=05"> May </a> (9) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2024&month=04"> April </a> (6) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2024&month=03"> March </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2024&month=02"> February </a> (6) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2024&month=01"> January </a> (6) </li> </ul> <h3> 2023 </h3> <ul class="ui-helper-reset"> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2023&month=12"> December </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2023&month=11"> November </a> (6) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2023&month=10"> October </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2023&month=09"> September </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2023&month=08"> August </a> (6) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2023&month=07"> July </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2023&month=06"> June </a> (8) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2023&month=05"> May </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2023&month=04"> April </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2023&month=03"> March </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2023&month=02"> February </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2023&month=01"> January </a> (6) </li> </ul> <h3> 2022 </h3> <ul class="ui-helper-reset"> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2022&month=12"> December </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2022&month=11"> November </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2022&month=10"> October </a> (5) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2022&month=09"> September </a> (6) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2022&month=08"> August </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2022&month=07"> July </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2022&month=06"> June </a> (8) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2022&month=05"> May </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2022&month=04"> April </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2022&month=03"> March </a> (8) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2022&month=02"> February </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2022&month=01"> January </a> (6) </li> </ul> <h3> 2021 </h3> <ul class="ui-helper-reset"> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2021&month=12"> December </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2021&month=11"> November </a> (4) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2021&month=10"> October </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2021&month=09"> September </a> (9) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2021&month=08"> August </a> (6) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2021&month=07"> July </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2021&month=06"> June </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2021&month=05"> May </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2021&month=04"> April </a> (8) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2021&month=03"> March </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2021&month=02"> February </a> (5) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2021&month=01"> January </a> (6) </li> </ul> <h3> 2020 </h3> <ul class="ui-helper-reset"> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2020&month=12"> December </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2020&month=11"> November </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2020&month=10"> October </a> (8) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2020&month=09"> September </a> (6) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2020&month=08"> August </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2020&month=07"> July </a> (9) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2020&month=06"> June </a> (8) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2020&month=05"> May </a> (8) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2020&month=04"> April </a> (10) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2020&month=03"> March </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2020&month=02"> February </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2020&month=01"> January </a> (7) </li> </ul> <h3> 2019 </h3> <ul class="ui-helper-reset"> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2019&month=12"> December </a> (6) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2019&month=11"> November </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2019&month=10"> October </a> (8) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2019&month=09"> September </a> (8) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2019&month=08"> August </a> (6) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2019&month=07"> July </a> (8) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2019&month=06"> June </a> (6) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2019&month=05"> May </a> (9) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2019&month=04"> April </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2019&month=03"> March </a> (10) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2019&month=02"> February </a> (9) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2019&month=01"> January </a> (6) </li> </ul> <h3> 2018 </h3> <ul class="ui-helper-reset"> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2018&month=12"> December </a> (9) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2018&month=11"> November </a> (9) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2018&month=10"> October </a> (9) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2018&month=09"> September </a> (11) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2018&month=08"> August </a> (9) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2018&month=07"> July </a> (9) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2018&month=06"> June </a> (12) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2018&month=05"> May </a> (9) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2018&month=04"> April </a> (10) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2018&month=03"> March </a> (11) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2018&month=02"> February </a> (11) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2018&month=01"> January </a> (10) </li> </ul> </div> </div> </div> </div> </div> </div>  </div> <section class="cgdp-page-options cgdp-page-options--bottom" aria-label="Page options bottom"> <button class="usa-button usa-button--unstyled" onclick="window.print()"> <svg xmlns="http://www.w3.org/2000/svg" height="24" viewBox="0 0 24 24" width="24" class="usa-icon" role="img" aria-hidden="true" focusable="false"> <path d="M0 0h24v24H0z" fill="none"/> <path d="M19 8H5c-1.66 0-3 1.34-3 3v6h4v4h12v-4h4v-6c0-1.66-1.34-3-3-3zm-3 11H8v-5h8v5zm3-7c-.55 0-1-.45-1-1s.45-1 1-1 1 .45 1 1-.45 1-1 1zm-1-9H6v4h12V3z"/> </svg> <span class="usa-sr-only"> Print </span> </button> <a class="usa-button usa-button--unstyled" href="mailto:?subject=Information from the National Cancer Institute Web Site &body=I found this information on www.cancer.gov and I'd like to share it with you: https://www.cancer.gov/news-events/cancer-currents-blog/2019/enzalutamide-apalutamide-metastatic-prostate-cancer %0D%0A%0D%0A NCI's Web site, www.cancer.gov, provides accurate, up-to-date, comprehensive cancer information from the U.S. government's principal agency for cancer research. If you have questions or need additional information, we invite you to contact NCI's LiveHelp instant messaging service at https://livehelp.cancer.gov, or call the NCI's Contact Center 1-800-4-CANCER (1-800-422-6237) (toll-free from the United States)."> <svg xmlns="http://www.w3.org/2000/svg" height="24" viewBox="0 0 24 24" width="24" class="usa-icon" role="img" aria-hidden="true" focusable="false"> <path d="M0 0h24v24H0z" fill="none"/> <path d="M20 4H4c-1.1 0-1.99.9-1.99 2L2 18c0 1.1.9 2 2 2h16c1.1 0 2-.9 2-2V6c0-1.1-.9-2-2-2zm0 14H4V8l8 5 8-5v10zm-8-7L4 6h16l-8 5z"/> </svg> <span class="usa-sr-only"> Email </span> </a> </section> </div> <div id="block-ncidsfooterenglish"> <footer class="usa-footer usa-footer--nci-big" id="nci-footer" aria-label="Footer" > <div class="grid-container usa-footer__return-to-top"> <a href="#top" aria-label="Back To Top"><span>Back To Top</span></a> </div> <div class="usa-footer__primary-section"> <div class="grid-container"> <div class="grid-row grid-gap"> <div class="tablet:grid-col-8"> <nav class="usa-footer__nav" aria-label="Footer navigation"> <div class="grid-row grid-gap-4"> <div class="mobile-lg:grid-col-6 desktop:grid-col-4"> <section class="usa-footer__primary-content usa-footer__primary-content--collapsible" > <div class="usa-footer__primary-link">About</div> <ul class="usa-list usa-list--unstyled"> <li class="usa-footer__secondary-link"> <a href="/about-website">About This Website</a> </li> <li class="usa-footer__secondary-link"> <a href="/espanol">en Español</a> </li> <li class="usa-footer__secondary-link"> <a href="/policies/copyright-reuse">Reuse & Copyright</a> </li> <li class="usa-footer__secondary-link"> <a href="/social-media">Social Media</a> </li> </ul> </section> </div> <div class="mobile-lg:grid-col-6 desktop:grid-col-4"> <section class="usa-footer__primary-content usa-footer__primary-content--collapsible" > <div class="usa-footer__primary-link">Resources</div> <ul class="usa-list usa-list--unstyled"> <li class="usa-footer__secondary-link"> <a href="/contact">Contact Us</a> </li> <li class="usa-footer__secondary-link"> <a href="/publications">Publications</a> </li> <li class="usa-footer__secondary-link"> <a href="/publications/dictionaries/cancer-terms" >Dictionary of Cancer Terms</a > </li> <li class="usa-footer__secondary-link"> <a href="/research/participate/clinical-trials-search" >Find a Clinical Trial</a > </li> </ul> </section> </div> <div class="mobile-lg:grid-col-6 desktop:grid-col-4"> <section class="usa-footer__primary-content usa-footer__primary-content--collapsible" > <div class="usa-footer__primary-link">Policies</div> <ul class="usa-list usa-list--unstyled"> <li class="usa-footer__secondary-link"> <a href="/policies/accessibility">Accessibility</a> </li> <li class="usa-footer__secondary-link"> <a href="/policies/foia">FOIA</a> </li> <li class="usa-footer__secondary-link"> <a href="/policies/privacy-security" >Privacy & Security</a > </li> <li class="usa-footer__secondary-link"> <a href="/policies/disclaimer">Disclaimers</a> </li> <li class="usa-footer__secondary-link"> <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" >Vulnerability Disclosure</a > </li> </ul> </section> </div> </div> </nav> </div> <div class="tablet:grid-col-4"> <div class="usa-sign-up"> <div class="usa-sign-up__heading">Sign up for email updates</div> <form action="https://public.govdelivery.com/accounts/USNIHNCI/subscribers/qualify" aria-label="Footer subscribe" class="usa-form" accept-charset="UTF-8" method="post" novalidate target="_blank" id="signup" > <input type="hidden" name="category_id" id="category_id" value="" /> <div class="usa-form-group"> <label class="usa-label" for="email"> Enter your email address </label> <input class="usa-input width-full" id="email" name="email" type="email" value="" /> </div> <button class="usa-button usa-button--accent-warm" type="submit"> Sign up </button> </form> </div> </div> </div> </div> </div> <div class="usa-footer__secondary-section"> <div class="grid-container"> <div class="grid-row grid-gap"> <div class="usa-footer__logo grid-row desktop:grid-col-5"> <div class="mobile-lg:grid-col-auto desktop:margin-bottom-3"> <p class="usa-footer__logo-heading"> <span class="logo__agency-name">National Cancer Institute </span> <span class="logo__parent-organization" >at the National Institutes of Health</span > </p> </div> </div> <div class="usa-footer__contact-links mobile-lg:grid-col-7"> <div class="usa-footer__contact-heading">Contact Us</div> <div class="usa-footer__address"> <div class="usa-footer__contact-info grid-row grid-gap"> <div class="tablet:grid-col-auto"> <a href="https://livehelp.cancer.gov/">Live Chat</a> </div> <div class="tablet:grid-col-auto"> <a href="tel:1-800-4-CANCER">1-800-4-CANCER</a> </div> <div class="tablet:grid-col-auto"> <a href="mailto:NCIinfo@nih.gov">NCIinfo@nih.gov</a> </div> <div class="tablet:grid-col-auto"> <a class="no-exit-notification" href="https://nci.az1.qualtrics.com/jfe/form/SV_aeLLobt6ZeGVn5I" target="_blank" >Site Feedback</a > </div> </div> </div> </div> </div> <div class="grid-row grid-gap"> <div class="usa-footer__social-links desktop:grid-col-5"> <div class="usa-footer__social-heading">Follow us</div> <div class="grid-row grid-gap-1 nci-big__social"> <div class="grid-col-auto"> <a class="usa-social-link no-exit-notification" href="https://www.facebook.com/cancer.gov" > <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" width="24" class="usa-icon" role="img" aria-labelledby="facebook-title" > <title id="facebook-title">Facebook</title> <rect fill="none" height="24" width="24" /> <path d="M22,12c0-5.52-4.48-10-10-10S2,6.48,2,12c0,4.84,3.44,8.87,8,9.8V15H8v-3h2V9.5C10,7.57,11.57,6,13.5,6H16v3h-2 c-0.55,0-1,0.45-1,1v2h3v3h-3v6.95C18.05,21.45,22,17.19,22,12z" /> </svg> </a> </div> <div class="grid-col-auto"> <a class="usa-social-link no-exit-notification" href="https://twitter.com/thenci" > <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" class="usa-icon" role="img" aria-labelledby="x-title" > <title id="x-title">Follow on X</title> <path d="M12 22c5.5 0 10-4.5 10-10S17.5 2 12 2 2 6.5 2 12s4.5 10 10 10zm5.2-15.6L13.3 11l4.3 6.2h-3.1L11.6 13 8 17.2h-.9l4.1-4.8-4.1-6h3.1l2.7 3.9 3.4-3.9h.9zm-5.6 5.4.4.6 2.8 4h1.4l-3.5-5-.4-.6-2.6-3.7H8.3l3.3 4.7z" /> </svg> </a> </div> <div class="grid-col-auto"> <a class="usa-social-link no-exit-notification" href="https://www.instagram.com/nationalcancerinstitute/" > <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" class="usa-icon" role="img" aria-labelledby="instagram-title" > <title id="instagram-title">Instagram</title> <g id="Instagram"> <path d="M12,10a2,2,0,1,0,2,2A2,2,0,0,0,12,10Z" /> <path d="M12,2A10,10,0,1,0,22,12,10,10,0,0,0,12,2Zm6,12.69A3.32,3.32,0,0,1,14.69,18H9.31A3.32,3.32,0,0,1,6,14.69V9.31A3.32,3.32,0,0,1,9.31,6h5.38A3.32,3.32,0,0,1,18,9.31Z" /> <path d="M16.94,9.31a2.25,2.25,0,0,0-2.25-2.25H9.31A2.25,2.25,0,0,0,7.06,9.31v5.38a2.25,2.25,0,0,0,2.25,2.25h5.38a2.25,2.25,0,0,0,2.25-2.25h0ZM12,15.09A3.09,3.09,0,1,1,15.09,12,3.09,3.09,0,0,1,12,15.09Zm3.77-5.75a.79.79,0,0,1-.55.23.83.83,0,0,1-.55-.23.78.78,0,0,1,0-1.11A.82.82,0,0,1,15.22,8a.78.78,0,0,1,.55,1.33Z" /> </g> </svg> </a> </div> <div class="grid-col-auto"> <a class="usa-social-link no-exit-notification" href="https://www.youtube.com/NCIgov" > <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" class="usa-icon" role="img" aria-labelledby="youtube-title" > <title id="youtube-title">Youtube</title> <g id="YouTube"> <path d="M12,2A10,10,0,1,0,22,12,10,10,0,0,0,12,2Zm5.75,12.91A1.49,1.49,0,0,1,16.69,16a34.65,34.65,0,0,1-4.69.26A34.65,34.65,0,0,1,7.31,16a1.49,1.49,0,0,1-1.06-1.06A15.88,15.88,0,0,1,6,12a15.88,15.88,0,0,1,.25-2.91A1.49,1.49,0,0,1,7.31,8,34.65,34.65,0,0,1,12,7.77,34.65,34.65,0,0,1,16.69,8a1.49,1.49,0,0,1,1.06,1.06A15.88,15.88,0,0,1,18,12,15.88,15.88,0,0,1,17.75,14.91Z" /> <polygon points="10.77 13.78 13.91 12 10.77 10.22 10.77 13.78" /> </g> </svg> </a> </div> <div class="grid-col-auto"> <a class="usa-social-link no-exit-notification" href="https://www.linkedin.com/company/nationalcancerinstitute/" > <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" class="usa-icon" role="img" aria-labelledby="linkedin-title" > <title id="linkedin-title">Linkedin</title> <g id="final"> <path d="M12,2C6.48,2,2,6.48,2,12s4.48,10,10,10s10-4.48,10-10S17.52,2,12,2z M8.912001,17.584H6.584v-7.472h2.328001V17.584z M7.744,9.104C6.992,9.104,6.4,8.488,6.4,7.76c0-0.752,0.592-1.344,1.344-1.344c0.728,0,1.343999,0.592,1.343999,1.344 C9.087999,8.488,8.472,9.104,7.744,9.104z M17.6,17.584h-2.328v-3.64c0-0.856-0.024001-1.967999-1.216001-1.967999 s-1.392,0.927999-1.392,1.912v3.696H10.36v-7.472h2.224v1.008h0.024c0.464-0.752,1.296-1.216001,2.199999-1.192 c2.352001,0,2.792,1.552001,2.792,3.544001C17.6,13.472,17.6,17.584,17.6,17.584z" /> </g> </svg> </a> </div> </div> </div> <div class="usa-footer__contact-links desktop:grid-col-7"> <div class="usa-footer__address height-full"> <div class="usa-footer__contact-info grid-row grid-gap height-full"> <address> <a href="https://www.hhs.gov/" >U.S. Department of Health and Human Services </a> <a href="https://www.nih.gov/" >National Institutes of Health </a> <a href="https://www.cancer.gov/">National Cancer Institute </a> <a href="https://usa.gov/">USA.gov</a> </address> </div> </div> </div> </div> </div> </div> </footer> </div> </div> <script src="/sites/g/files/xnrzdm211/files/js/js_qW3TLjdEty3QtOepUCSY4uh6BQEGkRIL3qUMnp3WXG4.js?scope=footer&delta=0&language=en&theme=ncids_trans&include=eJxFyEEOwCAIBMAPGX1SA4WoCVXCyqG_77FzHLw4-jQmaHEK6kE-0CTSyeo_NZcn28RQKeuegusELTS23fEB1Owbrg"></script> <script src="/profiles/custom/cgov_site/themes/custom/ncids_trans/dist/js/ncids-common.js?smm34w"></script> <script src="/profiles/custom/cgov_site/themes/custom/ncids_trans/dist/js/blogs.js?smm34w"></script> </body> </html>

CINXE.COM

Treatments Expanding for Metastatic Prostate Cancer - NCI